After 20 years of research and development validated by successful completion of phase three clinical trials, Sanofi Pasteur’s dengue vaccine has received a positive recommendation from the WHO, key decision-making guidance for dengue-endemic countries on implementation of public vaccination programs. The vaccine is today approved and available in some countries where dengue is highly endemic. Regulatory reviews and approvals are ongoing in others. For more information about “Sanofi Pasteur is committed to bringing the dengue vaccine first to countries where dengue is a major public health priority. That’s how the vaccine can have the greatest impact on the growing human and economic burden of disease. It’s a unique contribution to public health and a continuation of our company’s heritage: more than a century of developing and delivering innovative vaccines for people around the world. “ – David Loew, Executive Vice President, Sanofi and General Manager, Sanofi Pasteur.
FLIPPING THE MODEL
In the traditional pharmaceutical business model, a company releases a novel medical intervention to high-GDP nations, first. These markets get first access in exchange for price points that reward innovation, thereby underwriting access in lower-income countries, which typically get the solution less expensively, but several years alter. This model was essential to a company’s return on high research investment, ensuring robust re-investment in the next innovation. The incentives inherent to this model explain in part the scarcity of new solutions for many diseases endemic to low-income countries. Recognizing this, global public health institutions, US and EU governments and the pharmaceutical industry itself have buillt much-needed charitable development and delivery systems.There are models of this kind for malaria, HIV and tuberculosis, among others. When Sanofi Pasteur identificed a candidate dengue vaccine, we took the opportunity to ask the question: Would it be possile to develop and deliver a health soution designed for emerging markets that those countries could own and implement without seeking charitable support? In other words, could we design a vaccine solution with and for dengue-endemic nations? We blieved it would work: A new business model where an innovative vaccine is introduced first in the countries where the burden was highest, ensuring rapid access to innovation in order to have the greatest impact on the disease burden. It is a sustainable, social-value business model designed to better help prevent, control and manage dengue in collaboration with the country leadership on the frontlines of program implementation.